These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system. Claeson G Blood Coagul Fibrinolysis; 1994 Jun; 5(3):411-36. PubMed ID: 8075312 [TBL] [Abstract][Full Text] [Related]
7. Use of a dehydroalanine-containing peptide as an efficient inhibitor of tripeptidyl peptidase II. Tomkinson B; Grehn L; Fransson B; Zetterqvist O Arch Biochem Biophys; 1994 Nov; 314(2):276-9. PubMed ID: 7979365 [TBL] [Abstract][Full Text] [Related]
8. Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site. Tucker TJ; Lumma WC; Mulichak AM; Chen Z; Naylor-Olsen AM; Lewis SD; Lucas R; Freidinger RM; Kuo LC J Med Chem; 1997 Mar; 40(6):830-2. PubMed ID: 9083470 [No Abstract] [Full Text] [Related]
9. Synthesis of phosphopeptides containing O-phosphoserine and O-phosphothreonine. Arendt A; Hargrave PA Methods Mol Biol; 1994; 35():187-93. PubMed ID: 7894600 [No Abstract] [Full Text] [Related]
10. Design of novel types of thrombin inhibitors based on modified D-Phe-Pro-Arg sequences. Claeson G; Elgendy S; Cheng L; Chino N; Goodwin CA; Scully MF; Deadman J Adv Exp Med Biol; 1993; 340():83-9. PubMed ID: 8154346 [No Abstract] [Full Text] [Related]
11. Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors. Lin TY; Min HP; Jiang C; Niu MM; Yan F; Xu LL; Di B Bioorg Med Chem; 2018 Jul; 26(12):3429-3437. PubMed ID: 29807699 [TBL] [Abstract][Full Text] [Related]
12. Rational design of true hirudin mimetics: synthesis and characterization of multisite-directed alpha-thrombin inhibitors. Lombardi A; Nastri F; Della Morte R; Rossi A; De Rosa A; Staiano N; Pedone C; Pavone V J Med Chem; 1996 May; 39(10):2008-17. PubMed ID: 8642559 [TBL] [Abstract][Full Text] [Related]
13. The use of isosteric bonds in the design of thrombin inhibitors. Scully MF; Deadman J; Cheng L; Goodwin CA; Ellis V; Kakkar VV; Claeson G Adv Exp Med Biol; 1993; 340():131-41. PubMed ID: 8154330 [No Abstract] [Full Text] [Related]
14. Design of potent bivalent thrombin inhibitors based on hirudin sequence: incorporation of nonsubstrate-type active site inhibitors. Tsuda Y; Cygler M; Gibbs BF; Pedyczak A; Féthière J; Yue SY; Konishi Y Biochemistry; 1994 Dec; 33(48):14443-51. PubMed ID: 7981204 [TBL] [Abstract][Full Text] [Related]
15. Synthesis of O-phosphopeptides on solid phase. Singer D; Hoffmann R Methods Mol Biol; 2008; 494():209-22. PubMed ID: 18726576 [TBL] [Abstract][Full Text] [Related]
16. The synthesis and compositional analysis of phosphopeptides. Sanderson SD; Perini F Mol Biotechnol; 1995 Oct; 4(2):139-49. PubMed ID: 8556429 [TBL] [Abstract][Full Text] [Related]
17. The rational design of thrombin-directed antithrombotics. Fenton JW; Ni F; Witting JI; Brezniak DV; Andersen TT; Malik AB Adv Exp Med Biol; 1993; 340():1-13. PubMed ID: 8154327 [No Abstract] [Full Text] [Related]
18. The synthesis of phosphopeptides. McMurray JS; Coleman DR; Wang W; Campbell ML Biopolymers; 2001; 60(1):3-31. PubMed ID: 11376430 [TBL] [Abstract][Full Text] [Related]